繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

埃森哲应对市场挑战:第三季度超出预期,战略投资取得回报

2024-08-22 21:44

Agilent Technologies, Inc. (NYSE:A) shares are trading higher after the company reported third-quarter results yesterday.

Revenue fell 5.6% Y/Y to $1.58 billion, beating the consensus of $1.56 billion. By segment, the Life Sciences and Applied Markets Group (LSAG) segment reported revenue of $782 million, down 8% Y/Y (-7% Y/Y core), with an operating margin of 28.4%.

The Agilent CrossLab Group (ACG) revenue came in at $411 million, up 4% Y/Y (+5% Y/Y core), with an operating margin of 34.0%.

The Diagnostics and Genomics Group (DGG) revenue stood at $385 million, down 9% Y/Y (-8% Y/Y core), with an operating margin of 18.3%.

As of July 31, cash and cash equivalents stood at $1.78 billion. Adjusted EPS of $1.32 surpassed the street view of $1.26.

Outlook: Agilent forecasts fourth-quarter revenue of $1.641 billion – $1.691 billion (vs. $1.67 billion estimate) and adjusted EPS of $1.38 – $1.42 (vs. street view of $1.44).

For FY24, Agilent revised its revenue outlook to $6.45 billion – $6.5 billion from $6.42 billion – $6.5 billion (vs. $6.46 billion estimate) and adjusted EPS to $5.21 – $5.25 (vs. $5.20 estimate) from $5.15 – $5.25 earlier.

Agilent President and CEO Padraig McDonnell said, “While market conditions continued to be challenged during the quarter, we saw steady signs of improvement as anticipated. We continue to make investments in our most promising growth opportunities.”

“And we are mobilizing the organization to accelerate value creation through strategic transformation initiatives, which will drive margin expansion and growth—and increase our execution capabilities.”

Investors can gain exposure to the stock via ProShares Nanotechnology ETF (NYSE:TINY) and VanEck ETF Trust VanEck Morningstar Wide Moat Growth ETF (BATS:MGRO).

Price Action: A shares are up 1.88% at $142.63 at the last check Thursday.

Image from Shutterstock

Read Next:

  • EHang Q2 Revenue Skyrockets 920% with Record eVTOL Deliveries: Details

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。